You are here

  • Home
  • Archive
  • Volume 22, Issue Suppl 1
  • PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C

Article metrics

Article menu
Download PDFPDF
Patient safety and risk management
PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C

 

Online download statistics by month:

Online download statistics by month: March 2015 to August 2024

AbstractFullPdf
Mar 2015501
Apr 2015600
Jun 2015200
Jul 2015500
Sep 2015600
Oct 2015100
Nov 2015700
Dec 2015100
Jan 2016400
Feb 2016500
Apr 2016102
May 2016200
Jun 2016200
Jul 2016701
Aug 2016200
Sep 2016300
Oct 2016400
Nov 2016300
Dec 2016400
Jan 2017500
Feb 20172202
Mar 20174901
Apr 2017500
May 2017400
Jun 2017900
Jul 20171200
Aug 20172000
Sep 20171800
Oct 20172000
Nov 20172400
Dec 20173200
Jan 20184800
Feb 20185200
Mar 20186200
Apr 20185000
May 20183400
Jun 20184400
Jul 20181400
Aug 20181400
Sep 2018800
Oct 20185000
Nov 20184000
Dec 20186200
Jan 20194600
Feb 20194000
Mar 20191800
Apr 2019600
May 20191400
Jun 2019800
Jul 2019800
Aug 2019400
Sep 2019600
Oct 20191401
Nov 2019600
Dec 20191400
Jan 20201800
Feb 2020400
Mar 2020200
Apr 2020800
May 2020200
Jun 2020400
Jul 20201200
Aug 2020500
Sep 20201400
Oct 20201200
Nov 20201200
Dec 2020400
Jan 20211000
Feb 20211400
Mar 2021801
Apr 2021400
May 2021900
Oct 2021601
Nov 20212401
Dec 2021400
Jan 20221000
Feb 2022400
Mar 2022600
Apr 2022802
May 20221800
Jun 20221400
Jul 20221000
Aug 2022400
Sep 2022800
Oct 20221202
Nov 20221000
Dec 20221000
Jan 2023200
Feb 2023600
Mar 2023400
Apr 2023600
May 2023400
Jun 2023200
Jul 2023800
Aug 2023402
Sep 2023400
Oct 2023800
Nov 2023800
Dec 20231200
Jan 2024400
Feb 20241400
Mar 20241200
Apr 20241600
May 2024600
Jun 20241000
Jul 20241400
Aug 20242900
Total1415017